185 related articles for article (PubMed ID: 37500142)
1. T Cells Expressing CAR Equipped With Extracellular Domain of BTLA Are Effective Against HVEM-over-expressing Melanoma Cell Lines.
Kim Y; Kim JE; Lee DY; Choi JU; Park JS; Lee HK; Choi SU; Park S; Park CH
Anticancer Res; 2023 Aug; 43(8):3419-3427. PubMed ID: 37500142
[TBL] [Abstract][Full Text] [Related]
2. The BTLA-HVEM axis restricts CAR T cell efficacy in cancer.
Guruprasad P; Carturan A; Zhang Y; Cho JH; Kumashie KG; Patel RP; Kim KH; Lee JS; Lee Y; Kim JH; Chung J; Joshi A; Cohen I; Shestov M; Ghilardi G; Harris J; Pajarillo R; Angelos M; Lee YG; Liu S; Rodriguez J; Wang M; Ballard HJ; Gupta A; Ugwuanyi OH; Hong SJA; Bochi-Layec AC; Sauter CT; Chen L; Paruzzo L; Kammerman S; Shestova O; Liu D; Vella LA; Schuster SJ; Svoboda J; Porazzi P; Ruella M
Nat Immunol; 2024 Jun; 25(6):1020-1032. PubMed ID: 38831106
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
[TBL] [Abstract][Full Text] [Related]
4. Targeting BTLA with the peptide inhibitor HVEM(14-39) - A new way to restore the activity of T cells in melanoma.
Wojciechowicz K; Kuncewicz K; Rutkowski J; Jassem J; Rodziewicz-Motowidło S; Wardowska A; Spodzieja M
Biomed Pharmacother; 2024 Jun; 175():116675. PubMed ID: 38733770
[TBL] [Abstract][Full Text] [Related]
5. A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator.
Šedý JR; Balmert MO; Ware BC; Smith W; Nemčovičova I; Norris PS; Miller BR; Aivazian D; Ware CF
J Biol Chem; 2017 Dec; 292(51):21060-21070. PubMed ID: 29061848
[TBL] [Abstract][Full Text] [Related]
6. Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding.
Spodzieja M; Kuncewicz K; Sieradzan A; Karczyńska A; Iwaszkiewicz J; Cesson V; Węgrzyn K; Zhukov I; Maszota-Zieleniak M; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963646
[TBL] [Abstract][Full Text] [Related]
7. Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.
Boice M; Salloum D; Mourcin F; Sanghvi V; Amin R; Oricchio E; Jiang M; Mottok A; Denis-Lagache N; Ciriello G; Tam W; Teruya-Feldstein J; de Stanchina E; Chan WC; Malek SN; Ennishi D; Brentjens RJ; Gascoyne RD; Cogné M; Tarte K; Wendel HG
Cell; 2016 Oct; 167(2):405-418.e13. PubMed ID: 27693350
[TBL] [Abstract][Full Text] [Related]
8. Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
Spodzieja M; Lach S; Iwaszkiewicz J; Cesson V; Kalejta K; Olive D; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
PLoS One; 2017; 12(6):e0179201. PubMed ID: 28594868
[TBL] [Abstract][Full Text] [Related]
9. Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors.
Demerlé C; Gorvel L; Mello M; Pastor S; Degos C; Zarubica A; Angelis F; Fiore F; Nunes JA; Malissen B; Greillier L; Guittard G; Luche H; Barlesi F; Olive D
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230538
[TBL] [Abstract][Full Text] [Related]
10. BTLA interaction with HVEM expressed on CD8(+) T cells promotes survival and memory generation in response to a bacterial infection.
Steinberg MW; Huang Y; Wang-Zhu Y; Ware CF; Cheroutre H; Kronenberg M
PLoS One; 2013; 8(10):e77992. PubMed ID: 24205057
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic effects of B and T lymphocyte attenuator extracellular domain and heat shock protein 70 antigen peptide on cervical cancer in mouse model].
Han LF; Qiu WM; Hu C; Wang L; Yao HX; Xiong SY; Meng M; Fang Y; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):603-8. PubMed ID: 21029617
[TBL] [Abstract][Full Text] [Related]
12. Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway.
Cheung TC
Recent Pat DNA Gene Seq; 2009; 3(3):177-82. PubMed ID: 19702559
[TBL] [Abstract][Full Text] [Related]
13. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
Cai G; Freeman GJ
Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
[TBL] [Abstract][Full Text] [Related]
14. Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM.
Murphy TL; Murphy KM
Annu Rev Immunol; 2010; 28():389-411. PubMed ID: 20307212
[TBL] [Abstract][Full Text] [Related]
15. T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment.
Cheung TC; Oborne LM; Steinberg MW; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
J Immunol; 2009 Dec; 183(11):7286-96. PubMed ID: 19915044
[TBL] [Abstract][Full Text] [Related]
16. Clinical Significance of BTLA and HVEM Expression on Circulating CD4
Song HF; Chen XJ; Tang PJ; Xu P; Huang ZY; Wang XF
Viral Immunol; 2022 May; 35(4):291-302. PubMed ID: 35196150
[TBL] [Abstract][Full Text] [Related]
17. Herpes simplex virus glycoprotein D interferes with binding of herpesvirus entry mediator to its ligands through downregulation and direct competition.
Stiles KM; Whitbeck JC; Lou H; Cohen GH; Eisenberg RJ; Krummenacher C
J Virol; 2010 Nov; 84(22):11646-60. PubMed ID: 20826693
[TBL] [Abstract][Full Text] [Related]
18. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells.
Tao R; Wang L; Murphy KM; Fraser CC; Hancock WW
J Immunol; 2008 May; 180(10):6649-55. PubMed ID: 18453584
[TBL] [Abstract][Full Text] [Related]
19. BTLA inhibition has a dominant role in the
Battin C; Leitner J; Waidhofer-Söllner P; Grabmeier-Pfistershammer K; Olive D; Steinberger P
Front Immunol; 2022; 13():956694. PubMed ID: 36081508
[TBL] [Abstract][Full Text] [Related]
20. The expression and anatomical distribution of BTLA and its ligand HVEM in rheumatoid synovium.
Shang Y; Guo G; Cui Q; Li J; Ruan Z; Chen Y
Inflammation; 2012 Jun; 35(3):1102-12. PubMed ID: 22179929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]